Annual Revenue Comparison: Bristol-Myers Squibb Company vs Corcept Therapeutics Incorporated

Pharma Giants: Revenue Growth from 2014 to 2023

__timestampBristol-Myers Squibb CompanyCorcept Therapeutics Incorporated
Wednesday, January 1, 20141587900000026551000
Thursday, January 1, 20151656000000050286000
Friday, January 1, 20161942700000081321000
Sunday, January 1, 201720776000000159201000
Monday, January 1, 201822561000000251247000
Tuesday, January 1, 201926145000000306486000
Wednesday, January 1, 202042518000000353874000
Friday, January 1, 202146385000000365978000
Saturday, January 1, 202246159000000401858000
Sunday, January 1, 202345006000000482375000
Monday, January 1, 202448300000000
Loading chart...

Infusing magic into the data realm

A Tale of Two Companies: Revenue Growth from 2014 to 2023

In the competitive landscape of the pharmaceutical industry, Bristol-Myers Squibb Company and Corcept Therapeutics Incorporated have showcased contrasting revenue trajectories over the past decade. From 2014 to 2023, Bristol-Myers Squibb has seen its annual revenue soar by approximately 183%, peaking in 2021 with a staggering $46.4 billion. This growth reflects the company's strategic acquisitions and robust product pipeline.

Conversely, Corcept Therapeutics, a smaller player, has experienced a remarkable growth rate of over 1,700% during the same period, albeit from a much smaller base. Starting with a modest $26.6 million in 2014, Corcept's revenue reached nearly $482 million by 2023, driven by its niche focus on endocrinology and psychiatry.

This comparison highlights the diverse strategies and market positions of these two companies, offering insights into their financial health and future potential.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025